GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Cyclically Adjusted PB Ratio

Voyager Therapeutics (STU:VT6) Cyclically Adjusted PB Ratio : 1.36 (As of Sep. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-09-26), Voyager Therapeutics's current share price is €5.12. Voyager Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €3.77. Voyager Therapeutics's Cyclically Adjusted PB Ratio for today is 1.36.

The historical rank and industry rank for Voyager Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:VT6' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.41   Med: 2.04   Max: 2.5
Current: 1.41

During the past years, Voyager Therapeutics's highest Cyclically Adjusted PB Ratio was 2.50. The lowest was 1.41. And the median was 2.04.

STU:VT6's Cyclically Adjusted PB Ratio is ranked better than
51.66% of 604 companies
in the Biotechnology industry
Industry Median: 1.595 vs STU:VT6: 1.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Voyager Therapeutics's adjusted book value per share data for the three months ended in Jun. 2024 was €5.720. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.77 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Voyager Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Voyager Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Cyclically Adjusted PB Ratio Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.23

Voyager Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.23 2.31 1.93

Competitive Comparison of Voyager Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted PB Ratio falls into.



Voyager Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Voyager Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.12/3.77
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Voyager Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=5.72/132.5538*132.5538
=5.720

Current CPI (Jun. 2024) = 132.5538.

Voyager Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201409 0.000 100.428 0.000
201412 -1.148 99.070 -1.536
201503 0.000 99.621 0.000
201506 3.627 100.684 4.775
201509 -1.633 100.392 -2.156
201512 6.226 99.792 8.270
201603 5.848 100.470 7.715
201606 5.482 101.688 7.146
201609 5.227 101.861 6.802
201612 5.034 101.863 6.551
201703 4.438 102.862 5.719
201706 3.604 103.349 4.622
201709 2.723 104.136 3.466
201712 3.588 104.011 4.573
201803 2.500 105.290 3.147
201806 2.188 106.317 2.728
201809 1.740 106.507 2.166
201812 1.261 105.998 1.577
201903 2.436 107.251 3.011
201906 2.857 108.070 3.504
201909 2.667 108.329 3.263
201912 2.429 108.420 2.970
202003 1.952 108.902 2.376
202006 1.835 108.767 2.236
202009 3.788 109.815 4.572
202012 3.395 109.897 4.095
202103 3.047 111.754 3.614
202106 2.429 114.631 2.809
202109 1.967 115.734 2.253
202112 2.219 117.630 2.501
202203 1.803 121.301 1.970
202206 1.478 125.017 1.567
202209 2.093 125.227 2.215
202212 1.443 125.222 1.527
202303 4.665 127.348 4.856
202306 4.198 128.729 4.323
202309 3.760 129.860 3.838
202312 4.921 129.419 5.040
202403 5.774 131.776 5.808
202406 5.720 132.554 5.720

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Voyager Therapeutics  (STU:VT6) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Voyager Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics Business Description

Traded in Other Exchanges
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Voyager Therapeutics Headlines

No Headlines